Jasper Therapeutics reports Q1 EPS ($1.03), consensus ($1.22)

“We have continued to make strong progress advancing briquilimab during the first few months of the year,” said Ronald Martell, President and Chief Executive Officer of Jasper. “The BEACON and SPOTLIGHT studies in chronic urticarias are rapidly enrolling patients and we remain on track to disclose initial data from the studies in the third quarter of 2024 and second half of 2024, respectively. In addition, we recently announced our intention to advance briquilimab into clinical development in asthma, an indication in which we believe mast cell depletion via c-Kit inhibition has the potential to significantly impact disease control across all subtypes of the disease. With multiple clinical data readouts on the horizon in addition to the launch of our asthma development program, we are looking forward to an exciting and milestone rich second half of the year.”